Human papillomavirus testing for primary screening of cervical cancer precursors

被引:0
|
作者
Ratnam, S
Franco, EL
Ferenczy, A
机构
[1] McGill Univ, Dept Oncol, Montreal, PQ H2W 1S6, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ H2W 1S6, Canada
[3] Mem Univ Newfoundland, Fac Med, Div Community Med, Dept Hlth,Newfoundland Publ Hlth Lab, St Johns, NF A1B 3T2, Canada
[4] McGill Univ, Dept Pathol, Montreal, PQ H3T 1E2, Canada
[5] McGill Univ, Dept Obstet & Gynecol, Montreal, PQ H3T 1E2, Canada
[6] Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our objective was to determine whether the addition of human papillomavirus (HPV) testing to screening cytology improves the detection of cervical cancer precursors. Women of ages 18-69 gears underwent conventional Pap cytology and HPV DNA testing in a multicenter study in Newfoundland, Canada. Those with positive cytology and/or NPV and a random sample of those with dual negative results were referred for colposcopy. The study enrolled 2098 women. The relative sensitivity of HPV testing was significantly higher than cytology fur all-grade squamous intraepithelial lesions [SILs; 73%; 95% confidence interval (CI), 62-82] and high grade SILs (HSILs; 90%; 95% CI, 74-97) but had lower relative specificity (62% fur all-grade SILs and 51% for HSILs) than most cytological cutpoints. The rate of combined correct results for all-grade lesions was higher for HPV testing (68.8%) than for any cytological cutpoint (equivocal, 52.3%; LSILs, 51.6%; HSILs, 44.5%), The combination of HPV and an LSIL cutpoint had a negative predictive value of 68% (95% CI, 52-80) for all SILs and 100% (95% CI, 91-100) for HSILs, while referring For colposcopy only 12% of the women. We concluded that HPV testing in conjunction with cytology improved the screening efficacy of cytology alone and may allow for a more effective and safe primary screening program with increased screening intervals.
引用
收藏
页码:945 / 951
页数:7
相关论文
共 50 条
  • [1] Human papillomavirus testing for primary cervical cancer screening
    Meijer, CJLM
    Rozendaal, L
    vanderLinden, JC
    Helmerhorst, TJM
    Voorhorst, FJ
    Walboomers, JMM
    [J]. NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, 1997, : 338 - 347
  • [2] Human papillomavirus testing for primary cervical cancer screening
    Grce, Magdalena
    Davies, Philip
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (05) : 599 - 605
  • [3] Human papillomavirus testing for primary cervical cancer screening
    Carolyn D. Runowicz
    Stephanie Garozzo
    [J]. Current Oncology Reports, 2008, 10
  • [4] Human Papillomavirus Testing for Primary Cervical Cancer Screening
    Runowicz, Carolyn D.
    Garozzo, Stephanie
    [J]. CURRENT ONCOLOGY REPORTS, 2008, 10 (06) : 533 - 537
  • [5] Human papillomavirus testing for primary cervical cancer screening
    Cuzick, J
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (01): : 108 - 109
  • [6] Cervical cancer prevention: Human papillomavirus testing as primary screening
    Desai, Shreya
    Zhu, Michelle J.
    Lapidos-Salaiz, Ilana
    [J]. CANCER, 2022, 128 (05) : 939 - 943
  • [7] Human papillomavirus testing as a primary screening tool for cervical cancer
    Cho, Hyun-Woong
    Hong, Jin Hwa
    Lee, Jae Kwan
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2021, 32 (03)
  • [8] HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING
    SUN, XW
    KOULOS, JP
    FELIX, JC
    FERENCZY, A
    RICHART, RM
    PATH, TW
    WRIGHT, TC
    [J]. LANCET, 1995, 346 (8975): : 636 - 636
  • [9] Cervical screening: primary human papillomavirus testing
    Cruickshank, M. E.
    Cubie, H. A.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 (06) : 650 - 652
  • [10] HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING
    CUZICK, J
    SZAREWSKI, A
    TERRY, G
    HO, L
    HANBY, A
    MADDOX, P
    ANDERSON, M
    KOCJAN, G
    STEELE, ST
    GUILLEBAUD, J
    [J]. LANCET, 1995, 345 (8964): : 1533 - 1536